CYAD Celyad SA

20.12
+0.08  (+0%)
Previous Close 20.04
Open 20.12
Price To Book 3.87
Market Cap 240279961
Shares 11,942,344
Volume 261
Short Ratio
Av. Daily Volume 3,540

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data did not meet primary endpoint
C-Cure - Chart 1 trial
Chronic Heart Failure secondary to ischemic cardiomyopathy
Phase 1 update due at EHA June 15, 2019, 5:30pm.
CYAD-01 - THINK
Various cancers - solid and hematologic cancers
Phase 1 commencement of enrollment announced November 30, 2018 with top-line data due 2H 2019.
CYAD-101 - alloSHRINK
Colorectal cancer
Phase 1 data to be presented at ESMO July 3-6, 2019.
CYAD-01 and FOLFOX - SHRINK
Colorectal cancer
Phase 1 update due at EHA June 15, 2019, 5:30pm.
CYAD-01 and chemotherapy (DEPLETHINK)
AML or myelodysplastic syndrome (MDS)

Latest News

  1. Celyad to Present Data at 24th Congress of the European Hematology Association
  2. Celyad Announces First Quarter 2019 Financial Results and Recent Business Highlights
  3. Celyad Announces May 2019 Investor Conference Schedule
  4. Celyad to Present Update on allogeneic and autologous NKG2D-based CAR-T Candidates in Refractory mCRC at ESMO 21st World GI Congress
  5. Celyad Announces April 2019 Investor Conference Schedule
  6. Celyad Reports Business Update and Full Year 2018 Financial and Operating Results
  7. Celyad Appoints Filippo Petti as Chief Executive Officer
  8. Celyad’s 2019 R&D Day Highlights shRNA Platform and Pipeline of Next-generation NKG2D-based and Off-the-Shelf Non-gene Edited CAR-T Candidates
  9. Celyad to Host R&D Day and Webcast on Monday, March 18 in New York City
  10. Celyad Appoints Anne Moore as Vice President Corporate Strategy
  11. Celyad Announces February and March 2019 Investor Conference Schedule
  12. Celyad Outlines Key 2019 Priorities Including the Acceleration of the CYAD-01 Program in r/r AML and MDS
  13. Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting
  14. The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings
  15. Celyad Doses First mCRC Patient in the Phase 1 alloSHRINK Trial Evaluating Non-Gene Edited Allogeneic CAR-T Candidate, CYAD-101
  16. Celyad Announces Third Quarter 2018 Business Update
  17. Celyad to Participate at Upcoming Healthcare Conferences
  18. Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting
  19. Celyad to Present New CYAD-01 Data from THINK Study in Relapsed/Refractory Acute Myeloid Leukemia at 2018 ASH Annual Meeting
  20. Celyad (CYAD) Jumps: Stock Rises 6.8%